Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Slides:

Advertisements

Similar presentations

Regenerative Medicine Regenerative medicine~ Goal: to grow replacement tissue or organs for patients who have sustained an injury or have a disease that.

Advertisements

REGENERATIVE MEDICINE BIOMEDICAL TECHNOLOGY 1. Regenerative medicine is growing replacement tissue or organs for patients who have sustained an injury.

Regenerative Medicine Regenerative medicine~ Goal: to grow replacement tissue or organs for patients who have sustained an injury or have a disease that.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Low-grade inflammation in FGID

Figure 2 Exosome composition

Figure 4 The gut microbiota directly influences T-cell differentiation

promotes the oncogenic activity of CagA

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Treatment algorithm for perianal fistulizing disease

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 1 Gut microorganisms at the intersection of several diseases

Figure 5 Two approaches to therapeutic genome editing

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 3 The 'leaky gut' hypothesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Figure 2 Switching of biologic agents and biosimilars

REGENERATIVE MEDICINE

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

different types of liver cells

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Hepatic regeneration in ACLF

Figure 3 Serotonin influences many peripheral tissues

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 5 Chrononutrition in the liver

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Schematic of normal and abnormal liver regeneration

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Animal models of liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 5 Systems biological model of IBS

Figure 4 Local species pools that contribute to the

Figure 1 Cancer stem cell plasticity and stem cell homeostasis in the gut Figure 1 | Cancer stem cell plasticity and stem cell homeostasis in the gut.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 The spread of colorectal cancer metastases

Presentation transcript:

Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.124 Figure 2 An overview of gastrointestinal tract tissue engineering and regenerative medicine approaches Figure 2 | An overview of gastrointestinal tract tissue engineering and regenerative medicine approaches. The gastrointestinal tract is susceptible to different diseases that tissue engineering and regenerative medicine might be able to repair and treat. These can be divided into acellular approaches such as decellularized matrices, synthetic and natural scaffolds as replacements to reconstruct the gut, or cell-based approaches such as tissue-specific cells (smooth muscle cells, neural progenitor cells and epithelial cells), gut-derived organoid units and stem cells (organ buds). Bitar, K. N. & Zakhem, E. (2016) Bioengineering the gut: future prospects of regenerative medicine Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.124